MX378983B - Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos. - Google Patents

Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos.

Info

Publication number
MX378983B
MX378983B MX2017014300A MX2017014300A MX378983B MX 378983 B MX378983 B MX 378983B MX 2017014300 A MX2017014300 A MX 2017014300A MX 2017014300 A MX2017014300 A MX 2017014300A MX 378983 B MX378983 B MX 378983B
Authority
MX
Mexico
Prior art keywords
compositions
methods
histone deacetylase
deacetylase inhibitors
inhibitors
Prior art date
Application number
MX2017014300A
Other languages
English (en)
Spanish (es)
Other versions
MX2017014300A (es
Inventor
Alan F Haughan
de Poël Amanda Van
Andrew J Stott
Celia Dominguez
Christopher A Luckhurst
Elizabeth A Saville-Stones
Grant Wishart
Michael Wall
Michel C Maillard
Perla Breccia
Rebecca E Jarvis
Original Assignee
Chdi Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chdi Foundation Inc filed Critical Chdi Foundation Inc
Publication of MX2017014300A publication Critical patent/MX2017014300A/es
Publication of MX378983B publication Critical patent/MX378983B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
MX2017014300A 2015-05-07 2016-05-06 Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos. MX378983B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562158363P 2015-05-07 2015-05-07
PCT/US2016/031335 WO2016179554A1 (en) 2015-05-07 2016-05-06 Histone deacetylase inhibitors and compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
MX2017014300A MX2017014300A (es) 2018-08-09
MX378983B true MX378983B (es) 2025-03-10

Family

ID=57218014

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014300A MX378983B (es) 2015-05-07 2016-05-06 Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos.

Country Status (11)

Country Link
US (2) US10053434B2 (https=)
EP (1) EP3291810B1 (https=)
JP (1) JP6805172B2 (https=)
KR (1) KR20180002729A (https=)
CN (1) CN107735088B (https=)
AU (1) AU2016258188B2 (https=)
CA (1) CA2984618C (https=)
EA (1) EA036965B1 (https=)
IL (1) IL255448B2 (https=)
MX (1) MX378983B (https=)
WO (1) WO2016179554A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016256917B2 (en) 2015-05-07 2021-08-26 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
MX378983B (es) * 2015-05-07 2025-03-10 Chdi Foundation Inc Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos.
BR112019001229B1 (pt) * 2016-07-22 2022-11-16 Syngenta Participations Ag Composto derivado de oxadiazol, composição agroquímica compreendendo o mesmo, método para controlar ou impedir infestação de plantas úteis por microrganismos fitopatogênicos e uso do referido composto como fungicida
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
CN109627207A (zh) * 2018-12-17 2019-04-16 天津药明康德新药开发有限公司 一种3-(二氟甲氧基)哌啶盐酸盐的制备方法
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
US20240327361A1 (en) * 2021-02-15 2024-10-03 The Research Foundation For The State University Of New York Radiolabeled compositions and methods of use thereof
TW202345813A (zh) 2022-04-08 2023-12-01 美商艾科尼佐療法股份有限公司 㗁二唑hdac6抑制劑及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1828171B1 (en) 2004-12-10 2014-03-12 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Heterocycle derivatives as histone deacetylase (hdac) inhibitors
AU2011205283B2 (en) 2010-01-13 2014-07-10 Tempero Pharmaceuticals, Inc. Compounds and methods
WO2013006408A1 (en) * 2011-07-01 2013-01-10 Tempero Pharmaceuticals, Inc. Compounds and methods
EA201490228A1 (ru) * 2011-07-08 2014-08-29 Новартис Аг Новые производные трифторметилоксадиазола и их применение для лечения заболевания
WO2013009830A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
WO2013009810A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
SI2750677T1 (sl) * 2011-08-30 2017-10-30 Chdi Foundation, Inc. Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe
WO2013066835A2 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013066833A1 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods to inhibit histone deacetylase (hdac) enzymes
BR112014012815A8 (pt) 2011-11-28 2017-06-20 Novartis Ag derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença
KR20150000882A (ko) * 2012-04-05 2015-01-05 씨에이치디아이 파운데이션, 인코포레이티드 키뉴레닌-3-모노산소첨가효소 억제제들, 약학 조성물들 및 이의 사용 방법
AU2016256917B2 (en) 2015-05-07 2021-08-26 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
MX378983B (es) * 2015-05-07 2025-03-10 Chdi Foundation Inc Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos.
PL3328843T3 (pl) 2015-07-27 2023-02-27 Chong Kun Dang Pharmaceutical Corp. Związki będące pochodnymi 1,3,4 oksadiazolosulfonamidów jako inhibitor deacetylazy histonowej 6, oraz kompozycja farmaceutyczna je zawierająca
RU2695227C9 (ru) 2015-07-27 2020-03-04 Чонг Кун Данг Фармасьютикал Корп. Производные 1,3,4-оксадиазолсульфамида в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция
JP6491393B2 (ja) 2015-08-04 2019-03-27 チョン クン ダン ファーマシューティカル コーポレーション ヒストン脱アセチル化酵素6阻害剤としての1,3,4−オキサジアゾール誘導体化合物及びこれを含有する薬剤学的組成物

Also Published As

Publication number Publication date
CA2984618C (en) 2024-01-09
AU2016258188A1 (en) 2017-11-23
WO2016179554A1 (en) 2016-11-10
IL255448B2 (en) 2023-07-01
US10053434B2 (en) 2018-08-21
EP3291810B1 (en) 2022-08-10
EA201792247A1 (ru) 2018-06-29
IL255448B1 (en) 2023-03-01
US20190202795A1 (en) 2019-07-04
AU2016258188B2 (en) 2021-08-26
US20160326124A1 (en) 2016-11-10
CN107735088A (zh) 2018-02-23
JP2018515489A (ja) 2018-06-14
MX2017014300A (es) 2018-08-09
EP3291810A4 (en) 2018-11-07
JP6805172B2 (ja) 2020-12-23
HK1252487A1 (en) 2019-05-24
EP3291810A1 (en) 2018-03-14
EA036965B1 (ru) 2021-01-20
IL255448A0 (en) 2017-12-31
KR20180002729A (ko) 2018-01-08
CA2984618A1 (en) 2016-11-10
CN107735088B (zh) 2021-11-02
BR112017023711A2 (pt) 2018-07-17

Similar Documents

Publication Publication Date Title
MX379817B (es) Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos.
MX378983B (es) Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos.
CO2018005381A2 (es) Inhibidores éster de acc y usos de los mismos
CL2017000576A1 (es) Inhibidores de mk2 y sus usos
CO2018004124A2 (es) Compuestos heterocíclicos
CO2017002532A2 (es) Indazoles sustituidos con bencilo como inhibidores de bub1
PL3510033T3 (pl) Związki i kompozycje jako inhibitory endosomalnych receptorów toll- podobnych
CU20180001A7 (es) Derivados de oxopiridina sustituidos y procesos para su preparación
MX2019012434A (es) Agentes inductores de apoptosis.
EA201890749A1 (ru) ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) И ИХ ПРИМЕНЕНИЕ
HUE057041T2 (hu) Hiszton deacetiláz hetero-halogén gátlói
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
CL2015002394A1 (es) Inhibidores de histona desmetilasas
CR20180072A (es) Nuevos compuestos biciclicos como inhibidores de atx
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
EP3624804A4 (en) HISTONE DEACETYLASE INHIBITORS (HDAC)
HK1220407A1 (zh) 组蛋白去乙酰酶抑制剂,其组合物及其使用方法
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
EA201590028A1 (ru) Ингибиторы гистондеацетилазы и их композиции и способы их применения
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
HK1220406A1 (zh) 组蛋白去乙酰酶抑制剂及组合物
EP3820859C0 (en) HISTONE DEACETYLASE INHIBITORS
MX2018000175A (es) Compuestos de arilsulfonamida como inhibidores de la anhidrasa carbonica y su uso terapeutico.
CL2017000440A1 (es) Variantes de inhibidor de tejido de metaloproteinasa tipo tres (timp-3), composiciones y metodos